Ignite Creation Date:
2025-12-24 @ 1:40 PM
Ignite Modification Date:
2026-01-04 @ 12:09 AM
Study NCT ID:
NCT00329095
Status:
COMPLETED
Last Update Posted:
2006-05-24
First Post:
2006-05-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D005901', 'term': 'Glaucoma'}, {'id': 'D009798', 'term': 'Ocular Hypertension'}, {'id': 'D010349', 'term': 'Patient Compliance'}], 'ancestors': [{'id': 'D005128', 'term': 'Eye Diseases'}, {'id': 'D010342', 'term': 'Patient Acceptance of Health Care'}, {'id': 'D000074822', 'term': 'Treatment Adherence and Compliance'}, {'id': 'D015438', 'term': 'Health Behavior'}, {'id': 'D001519', 'term': 'Behavior'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000069557', 'term': 'Travoprost'}, {'id': 'D000077338', 'term': 'Latanoprost'}, {'id': 'D000069580', 'term': 'Bimatoprost'}], 'ancestors': [{'id': 'D003008', 'term': 'Cloprostenol'}, {'id': 'D011461', 'term': 'Prostaglandins F, Synthetic'}, {'id': 'D011465', 'term': 'Prostaglandins, Synthetic'}, {'id': 'D011453', 'term': 'Prostaglandins'}, {'id': 'D015777', 'term': 'Eicosanoids'}, {'id': 'D005231', 'term': 'Fatty Acids, Unsaturated'}, {'id': 'D005227', 'term': 'Fatty Acids'}, {'id': 'D008055', 'term': 'Lipids'}, {'id': 'D012898', 'term': 'Autacoids'}, {'id': 'D018836', 'term': 'Inflammation Mediators'}, {'id': 'D001685', 'term': 'Biological Factors'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DIAGNOSTIC', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'count': 60}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2005-12'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2006-05', 'completionDateStruct': {'date': '2006-04'}, 'lastUpdateSubmitDate': '2006-05-22', 'studyFirstSubmitDate': '2006-05-19', 'studyFirstSubmitQcDate': '2006-05-22', 'lastUpdatePostDateStruct': {'date': '2006-05-24', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2006-05-24', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Compliance.'}]}, 'conditionsModule': {'keywords': ['Glaucoma', 'Compliance'], 'conditions': ['Glaucoma', 'Ocular Hypertension']}, 'referencesModule': {'references': [{'pmid': '17686450', 'type': 'DERIVED', 'citation': 'Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007 Oct;144(4):533-40. doi: 10.1016/j.ajo.2007.06.012. Epub 2007 Aug 8.'}]}, 'descriptionModule': {'briefSummary': 'This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.', 'detailedDescription': 'This is an open-label study in patients who are currently using either a topical prostaglandin as sole ocular hypotensive medical therapy q.d., or a topical prostaglandin plus an adjunctive topical ocular hypotensive marketed product either q.d., or b.i.d. in the same eye(s). Compliance will be measured over the two months of participation.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Currently using one or two topical ocular hypotensive medications\n\nExclusion Criteria:\n\n* Hypersensitivity to any component of medication'}, 'identificationModule': {'nctId': 'NCT00329095', 'briefTitle': 'An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance', 'organization': {'class': 'INDIV', 'fullName': 'Robin, Alan L., M.D.'}, 'officialTitle': 'An Evaluation of Use of Topical Ocular Hypotensive Medication by Electronic Compliance Measures', 'orgStudyIdInfo': {'id': 'GMED-01'}}, 'armsInterventionsModule': {'interventions': [{'name': 'travoprost, latanoprost, or bimatoprost', 'type': 'DRUG'}, {'name': 'Additional ocular hypotensive medication', 'type': 'DRUG'}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Alan L. Robin, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Alan L. Robin, M.D.'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Robin, Alan L., M.D.', 'class': 'INDIV'}}}}